The dose response experiments demonstrated that C-6 had comparable activity and selectivity for cancer cells representing the major subtypes of breast cancer including ER+ (MCF-7, T47D and PE1008032 cells), triple negative (MDA-MB-231 and PE1007070 cells) and HER2+ (PE904557a cells) (Figure 2C and 2D). The gene discussed is ERBB2; the disease is cancer.